Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLY)
$ 7.36 +0.010 (+0.14%) Market Cap: 371.17 Mil Enterprise Value: 209.93 Mil PE Ratio: 17.44 PB Ratio: 2.07 GF Score: 84/100

Half Year 2026 Clinuvel Pharmaceuticals Ltd Earnings Call Transcript

Feb 26, 2026 / 07:00AM GMT
Release Date Price: $7.88 (-4.43%)
Malcolm Bull
Clinuvel Pharmaceuticals Ltd - Head of Australian Operations and Investor Relations

So for today's webinar, noting this is not the forum for a strategic review, but as a courtesy to you all, we include Doctor Rodenberger and Doctor 10 to answer questions and provide their insights direct to you.

Today's webinar will be in two parts, first, a discussion of the half-year results, and second, the analysts online will be called upon to ask questions of the CFO and management.

We will be talking today about plans and intended outcomes, so draw your attention to the forward-looking statement or safe harbor statement on screen that identifies a range of risks that can materialize and impact their achievement.

So I think ten seconds to review that is enough, and that is on our website and on all of our announcements.

I now kindly invite the CFO to summarize the results, Peter.

Peter Vaughan
Clinuvel Pharmaceuticals Ltd - Chief Financial Officer

Thanks, Malcolm.

Good evening and good morning everyone from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot